Dr. Samuel H. Selesnick, MD

Dr. Selesnick practices at Columbia University Irving Medical Center in New York, New York.

Dr. Selesnick's NPI, 1699701557, was assigned on June 23, 2006. Dr. Selesnick graduated from New York University School of Medicine in 1985. Dr. Selesnick holds New York license 167180.

Dr. Selesnick's primary practice is Columbia University Irving Medical Center, at 622 W 168th St, New York, NY 10032 in New York County. The practice phone is (212) 305-4920.

Dr. Selesnick's primary practice is Columbia University Irving Medical Center in New York, New York. Dr. Selesnick is also affiliated with NewYork-Presbyterian/Weill Cornell Medical Center. The medical group on file is Weill Cornell Physicians. Dmand AI also links Dr. Selesnick to 1 more group practice or clinic, named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Selesnick practices, 2 sites in all. Vendor and product names are available with a free account.

Otolaryngology is Dr. Selesnick's primary specialty in the NPI Registry, under taxonomy code 207Y00000X. Dr. Selesnick is board certified in neurotology by the American Board of Otolaryngology - Head and Neck Surgery. Dmand AI has Dr. Selesnick's licenses on file in 3 states: New York, California and New Jersey.

Dmand AI lists chronic ear infection, ear eustachian tube disorders, ear infection, hearing loss and impairment, swimmer's ear, tinnitus, upper respiratory infection (URI) and vertigo among the conditions Dr. Selesnick treats.

CMS data shows 739 Medicare services from Dr. Selesnick across 8 procedure codes in 2024, for 257 Medicare patients. Medicare paid $57,011 for them. Every service was in an office.

CMS counts 257 Medicare patients who saw Dr. Selesnick in 2024. The largest group is 65 to 74, with 109 patients. 75% of them have high cholesterol, and 67% have high blood pressure. 9% are also on Medicaid. Their average risk score is 1.26, where 1.00 is the Medicare average.

Across all payers, Dmand AI patient panel data puts Dr. Selesnick's median patient age at 61, with 49% women.

In 2024, Dr. Selesnick wrote 72 Medicare Part D claims for 32 patients. 93% of them were for generic drugs. CMS names the drug for 11 of them, across 1 drug with 11 or more claims each, at $1,176 in total drug cost. In 2022, CMS named 37 claims across 2 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 100 out of 100 for Dr. Selesnick for performance year 2024, reported through an alternative payment model (APM). Dr. Selesnick accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Selesnick as offering telehealth.

Dmand AI links 88 papers to Dr. Selesnick, published from 2011 to 2025. 2020 was the busiest year, with 6. The most frequent topics are Neuroma, Acoustic, Magnetic Resonance Imaging and Otolaryngology. Dr. Selesnick has published most often in Otol Neurotol. Dr. Selesnick's most frequent co-authors are Lawrence R. Lustig, MD, Michael J. Link, MD and Rakesh Chandra, MD.

Dmand AI links Dr. Selesnick to 1 clinical trial. Conditions studied include Neuroma, Acoustic and Retrocochlear Diseases.

CMS Open Payments shows 1 general payment to Dr. Selesnick from 1 drug or device company in 2024. Food and beverage make up the largest share, 100% of the total. Advanced Bionics, LLC paid the most, $50.

Dmand AI lists 6 awards for Dr. Selesnick, most recently Top Doctors: New York Metro Area in 2014.

Dr. Selesnick graduated from New York University School of Medicine in 1985. Dr. Selesnick is a member of NHS and ACS.

Dr. Selesnick is in network with 16 carriers, including Aetna, Elevance and Excellus BlueCross BlueShield. PPO plans come from the most carriers, 11. Check the plan with the practice before a visit.